AKT1 and central nervous system cancer: found that MTCH2 knockdown impaired cell migration and invasion by repressing AKT signaling.[25] Meanwhile, they observed a close correlation between MTCH2 expression and poor patient survival in glioma.[25] Consistent with the study of gliomas, we found that higher MTCH2 expression exhibited poor outcomes.